SCHEDULE: OnKure Therapeutics: Trails Edge Discloses 6% Stake
Beneficial Ownership Filing
Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai have reported beneficial ownership of 6.0% of OnKure Therapeutics, Inc.'s Class A Common Stock as of March 31, 2026.
Summary
- Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP, and Ortav Yehudai (collectively, the "Filers") have filed a Schedule 13G, indicating their beneficial ownership of 2,409,638 shares of OnKure Therapeutics, Inc. Class A Common Stock.
- This holding represents 6.0% of the Issuer's outstanding shares as of March 31, 2026.
- The shares are held directly by Trails Edge Biotechnology Master Fund, LP.
- Trails Edge Capital Partners, LP acts as the investment manager for Trails Edge Biotechnology Master Fund, LP.
- Ortav Yehudai, as Chief Investment Officer of Trails Edge Capital Partners, LP, exercises voting and investment discretion over these shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership and does not provide operational or financial performance updates.
Positives
- Significant stake reported by a notable investment entity, potentially indicating confidence in the company's future.
- The filing clearly delineates the beneficial ownership structure, providing transparency.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the company.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates a notable position by Trails Edge in OnKure Therapeutics, which operates in the biotechnology sector, an industry characterized by innovation and significant capital requirements.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by an investment firm may influence market perception and trading activity.
- Management: The filing provides transparency on major beneficial owners, which is a standard aspect of corporate governance.
Key Dates
| Date | Description |
|---|---|
| 2025-12-31 | Year-end for the Annual Report on Form 10-K. |
| 2026-03-11 | Date as of which shares of Common Stock were issued and outstanding, as reported in the Form 10-K. |
| 2026-03-12 | Date OnKure Therapeutics filed its Annual Report on Form 10-K for the year ended December 31, 2025. |
| 2026-03-26 | Date of the private placement of Common Stock. |
| 2026-03-30 | Date OnKure Therapeutics reported its private placement in a Current Report on Form 8-K. |
| 2026-03-31 | Event Date, as of which beneficial ownership is reported and the number of outstanding shares is calculated. |
| 2026-04-07 | Date of signatures on the Schedule 13G filing. |
Keywords
OnKure Therapeutics, Schedule 13G, Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, Ortav Yehudai, Class A Common Stock, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.